FDA to give Salix IBS drug priority review

08/11/2010 | American City Business Journals

The FDA said it would give priority review to Xifaxan, from Salix Pharmaceuticals, as a treatment for irritable bowel syndrome. The drug already is approved for traveler's diarrhea and hepatic encephalopathy, and Phase III clinical trials showed it lessens the abdominal pain and bloating of IBS.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL